

DAFTAR PUSTAKA

1. Tamondong-Lachica DR, Skolnik N, Hurst JR, Marchetti N, Rabe APJ, Montes de Oca M, et al. GOLD 2023 update: implications for clinical practice. *Int J Chron Obstruct Pulmon Dis.* 2023;745–54.
2. Batte C, Semulimi AW, Mutebi RK, Twinamasiko N, Muyama SR, Mukisa J, et al. Cross-sectional validation of the COPD Assessment Test (CAT) among chronic obstructive pulmonary disease patients in rural Uganda. *PLOS Glob Public Heal.* 2023;3(6):e0002013.
3. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med.* 2022;10(5):447–58.
4. Cheng SL, Lin CH. Copd guidelines in the asia-pacific regions: Similarities and differences. *Diagnostics.* 2021;11(7):1–11.
5. Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. *J Cachexia Sarcopenia Muscle.* 2020;11(5):1164–76.
6. Martínez-Luna N, Orea-Tejeda A, González-Islas D, Flores-Cisneros L, Keirns-Davis C, Sánchez-Santillán R, et al. Association between body composition, sarcopenia and pulmonary function in chronic obstructive pulmonary disease. *BMC Pulm Med.* 2022;22(1):106.
7. Ma K, Huang F, Qiao R, Miao L. Pathogenesis of sarcopenia in chronic obstructive pulmonary disease. *Front Physiol.* 2022;13:850964.
8. Benz E, Trajanoska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, et al. Sarcopenia in COPD: a systematic review and meta-analysis. *Eur Respir Rev.* 2019;28(154).
9. Choi YJ, Kim T, Park HJ, Cho JH, Byun MK. Long-term clinical outcomes of patients with chronic obstructive pulmonary disease with sarcopenia. *Life.* 2023;13(8):1628.
10. Limpawattana P, Inthasuwan P, Putraveephong S, Boonsawat W, Theerakulpisut D, Sawanyawisuth K. Sarcopenia in chronic obstructive pulmonary disease: a study of prevalence and associated factors in the Southeast Asian population. *Chron Respir Dis.* 2018;15(3):250–7.
11. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. *Int J Chron Obstruct Pulmon Dis.* 2017;669–75.
12. Wankatesan P. GOLD COPD report: 2023 update. *Lancet Respir Med.* 2023;11(1):18.



13. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Eur Respir J.* 2023;61(4).
14. Boers E, Barrett M, Vuong V, Benjafield A, Su J, Kaye L, et al. An estimate of the global COPD prevalence in 2050: Disparities by income and gender. *Eur Respiratory Soc*; 2022.
15. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. *East Mediterr Heal J.* 2019;25(1):47–57.
16. Alfahad AJ, Alzaydi MM, Aldossary AM, Alshehri AA, Almughem FA, Zaidan NM, et al. Current views in chronic obstructive pulmonary disease pathogenesis and management. *Saudi Pharm J.* 2021;29(12):1361–73.
17. Walters EH, Shukla SD, Mahmood MQ, Ward C. Fully integrating pathophysiological insights in COPD: an updated working disease model to broaden therapeutic vision. *Eur Respir Rev.* 2021;30(160).
18. Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases (2023 report). *A Guid Heal Care Prof.* 2023;1(3):261–6.
19. Kritek P. 2023 GOLD Guidelines for Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med.* 2023;
20. Eom JS, Song WJ, Yoo H, Jeong BH, Lee HY, Koh WJ, et al. Chronic obstructive pulmonary disease severity is associated with severe pneumonia. *Ann Thorac Med.* 2015;10(2):105–11.
21. Lipovec NC, Schols AMWJ, van den Borst B, Beijers RJ, Kosten T, Omersa D, et al. Sarcopenia in advanced COPD affects cardiometabolic risk reduction by short-term high-intensity pulmonary rehabilitation. *J Am Med Dir Assoc.* 2016;17(9):814–20.
22. van Bakel SIJ, Gosker HR, Langen RC, Schols AMWJ. Towards personalized management of sarcopenia in COPD. *Int J Chron Obstruct Pulmon Dis.* 2021;25–40.
23. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am Med Dir Assoc.* 2020;21(3):300-307.e2.
24. Tsekoura M, Tsepis E, Billis E, Gliatis J. Sarcopenia in patients with chronic obstructive pulmonary disease: A study of prevalence and associated factors in a Western Greek population. *Lung India.* 2020;37(6):479–84.
25. Jones SE, Maddocks M, Kon SSC, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to



- pulmonary rehabilitation. *Thorax*. 2015;70(3):213–8.
26. He J, Li H, Yao J, Wang Y. Prevalence of sarcopenia in patients with COPD through different musculature measurements: an updated meta-analysis and meta-regression. *Front Nutr*. 2023;10:1137371.
 27. Costa TM da RL, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZC. Sarcopenia in COPD: relationship with COPD severity and prognosis. *J Bras Pneumol*. 2015;41:415–21.
 28. Chung JH, Hwang HJ, Han CH, Son BS, Kim DH, Park MS. Association between sarcopenia and metabolic syndrome in chronic obstructive pulmonary disease: The Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011. *COPD J Chronic Obstr Pulm Dis*. 2015;12(1):82–9.
 29. Demircioğlu H, Cihan FG, Kutlu R, Yosunkaya Ş, Zamani A. Frequency of sarcopenia and associated outcomes in patients with chronic obstructive pulmonary disease. *Turkish J Med Sci*. 2020;50(5):1270–9.

